PROCEPT BioRobotics (PRCT) & Its Competitors Critical Contrast

PROCEPT BioRobotics (NASDAQ:PRCTGet Rating) is one of 216 public companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare PROCEPT BioRobotics to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and target prices for PROCEPT BioRobotics and its rivals, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PROCEPT BioRobotics 0 1 6 0 2.86
PROCEPT BioRobotics Competitors 626 3051 7232 163 2.63

PROCEPT BioRobotics presently has a consensus price target of $42.71, suggesting a potential upside of 1.60%. As a group, “Surgical & medical instruments” companies have a potential upside of 32.49%. Given PROCEPT BioRobotics’ rivals higher probable upside, analysts clearly believe PROCEPT BioRobotics has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

65.7% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 50.9% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 40.8% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 14.7% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares PROCEPT BioRobotics and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
PROCEPT BioRobotics $34.47 million -$59.85 million -17.09
PROCEPT BioRobotics Competitors $1.14 billion $83.89 million -512.35

PROCEPT BioRobotics’ rivals have higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares PROCEPT BioRobotics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PROCEPT BioRobotics -138.49% -25.71% -20.45%
PROCEPT BioRobotics Competitors -738.88% -55.34% -19.44%

Summary

PROCEPT BioRobotics beats its rivals on 6 of the 11 factors compared.

PROCEPT BioRobotics Company Profile

(Get Rating)

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

Receive News & Ratings for PROCEPT BioRobotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PROCEPT BioRobotics and related companies with MarketBeat.com's FREE daily email newsletter.